春立医疗(688236) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 229,843,941.53, representing a 3.60% increase compared to CNY 221,850,180.79 in the same period last year[4]. - Net profit attributable to shareholders was CNY 58,071,117.89, up 5.20% from CNY 55,199,616.28 year-on-year[4]. - The net profit excluding non-recurring gains and losses was CNY 52,698,123.38, reflecting a 7.81% increase from CNY 48,882,462.10 in the previous year[4]. - Basic and diluted earnings per share were both CNY 0.15, an increase of 7.14% from CNY 0.14 in the same quarter last year[4]. - Total operating revenue for Q1 2025 reached CNY 229,843,941.53, an increase of 3.4% compared to CNY 221,850,180.79 in Q1 2024[18]. - Net profit for Q1 2025 was CNY 58,030,577.70, representing a 3.5% increase from CNY 55,107,063.21 in Q1 2024[19]. - Earnings per share for Q1 2025 were CNY 0.15, up from CNY 0.14 in Q1 2024[20]. Research and Development - Total R&D investment amounted to CNY 26,897,460.32, a decrease of 23.13% from CNY 34,991,868.71 in the previous year, with R&D expenses accounting for 11.70% of operating revenue, down from 15.77%[4]. - Research and development expenses for Q1 2025 totaled CNY 26,897,460.32, down from CNY 34,991,868.71 in Q1 2024[18]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 3,473,532,404.39, a slight increase of 0.22% from CNY 3,465,734,982.98 at the end of the previous year[5]. - The total current liabilities decreased from RMB 227,845,174.60 to RMB 198,903,468.21, a reduction of approximately 12.7%[16]. - The company's total liabilities decreased to CNY 594,157,689.89 from CNY 644,390,846.18 year-over-year[18]. - The total equity attributable to shareholders increased to CNY 2,877,973,401.17 from CNY 2,819,902,283.28[18]. Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of CNY -75,343,585.60 compared to CNY -129,613,339.07 in the same period last year[4][9]. - Cash flow from operating activities in Q1 2025 was CNY 154,928,044.70, a decrease from CNY 211,271,503.82 in Q1 2024[21]. - Operating cash inflow totaled $160,007,655.13, a decrease from$217,425,731.31 year-over-year[22]. - Operating cash outflow amounted to $235,351,240.73, down from$347,039,070.38 year-over-year[22]. - Net cash flow from operating activities was -$75,343,585.60, compared to -$129,613,339.07 in the previous year[22]. - Cash and cash equivalents at the end of the period were $1,796,034,364.28, compared to$1,220,123,829.78 at the end of the previous year[23]. - The net increase in cash and cash equivalents was $657,016,713.62, contrasting with a decrease of$45,889,245.89 in the prior year[23]. Shareholder Information - The company reported a total of 7,182 ordinary shareholders, with 7,167 holding A shares and 15 holding H shares[14]. - The top ten shareholders include Beijing Panmao Investment Management Co., Ltd. with 17,250,000 shares, representing a significant stake in the company[14]. - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[15]. Other Information - The company received government subsidies amounting to CNY 1,038,221.69, which are closely related to its normal business operations[6]. - Non-recurring gains and losses totaled CNY 5,372,994.51 after tax and minority interest adjustments[7]. - The company has not disclosed any significant new strategies or product developments during the reporting period[15]. - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[23].